The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Cerdulatinib in Relapsed/Refractory B-Cell Malignancies

Ian W. Flinn, MD, PhD
Published Online: 6:28 PM, Wed June 3, 2015

Ian W. Flinn, MD, PhD, director, Blood Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase I story which examined cerdulatinib in patients with relapsed/refractory B-cell malignancies.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.